ADIL logo

ADIAL PHARMACEUTICALS INC

ADILNASDAQ
๐Ÿ† #4719 by market capEarnings Mar 3 ยท PostUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track ADIL
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$12M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data
No chart data available for ADIL.

Trading Snapshot

Day Range
โ€”
52-Week Range
$1.31 โ€“ $8.25
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
3.1M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-16.57
Dividend Yield
โ€”
ADIL logo

ADIAL PHARMACEUTICALS INC

ADIL
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ADIAL PHARMACEUTICALS INC

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy2
Buy6
Hold2
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.